Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Anastrozole & Breast Cancer / Mammacarcinoma (HR+) (ER+) (Her2-)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Anastrozole is FDA- and EMA-approved for the treatment of Breast Cancer / Mammacarcinoma (HR+) (ER+) (Her2-), both in the early and advanced settings, particularly in postmenopausal women (1, 2)

(1) Kim & Lukong 2025 Oncol Rev 19: 1564642
(2) Obiorah & Jordan 2011 Maturitas 70(4): 315-21

…

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Bidard et al. 2022 J Clin Oncol 40(28): 3246-3256
Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
Jacobson 2022 Oncologist 27(Suppl 1): S7-S8
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Bardia et al. 2024 Clin Cancer Res 30(19): 4299-4309
Progress in endocrine approaches to the treatment and prevention of breast cancer
Obiorah & Jordan 2011 Maturitas 70(4): 315-21
Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action
Kim & Lukong 2025 Oncol Rev 19: 1564642
Review

7/1/2026